Overview

Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.

Status:
Withdrawn

Trial end date:
2022-10-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the effect of ticagrelor vs placebo for the reduction of Vaso-Occlusive crises in paediatric patients with Sickle Cell Disease

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Iqvia Pty Ltd

Treatments:

Ticagrelor